Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it a nice addition to the company’s ERT portfolio; this is likely the first business development deal in 2025. Before market open on Friday, BioMarin disclosed a definitive agreement to acquire Inozyme Pharma (INZY) for $4.00/share in an all-cash transaction for a total consideration of $270M. Leerink says it had been waiting for BioMarin to do some business development as it knew it was going to be part of their strategy moving forward, especially with James Sabry as Chief Business Officer. Overall, the firm thinks this first deal complements BioMarin’s existing infrastructure and expertise in ERTs very nicely and looks forward to additional potential BD transactions to further supplement the company’s pipeline. Leerink reiterates an Outperform rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Read More on BMRN:
DJ Kamal Mustafa
I’m DJ Kamal Mustafa, the founder and Editor-in-Chief of EMEA Tribune, a digital news platform that focuses on critical stories from Europe, the Middle East, Africa, and Pakistan. With a deep passion for investigative journalism, I’ve built a reputation for delivering exclusive, thought-provoking reports that highlight the region’s most pressing issues.
I’ve been a journalist for over 10 years, and I’m currently associated with EMEA Tribune, ARY News, Daily Times, Samaa TV, Minute Mirror, and many other media outlets. Throughout my career, I’ve remained committed to uncovering the truth and providing valuable insights that inform and engage the public.
